News

US biopharmaceutical firm Exelixis discovered and developed Cabometyx, which is claimed to be the first and only therapy approved in the European Union to demonstrate enhanced overall survival,

MacroGenics has regained the worldwide rights to MGD010, a bispecific molecule targeting CD32B and CD79B. Takeda’s decision comes earlier than the predefined expiration of its option exercise period

"XmAb14045 is a bispecific antibody that engages the immune system against AML," said Paul Foster, M.D., chief medical officer at Xencor. "Built on the scaffold of Xencor's XmAb

The products are currently sold at several large retailers including Rite-Aid, CVS, Wal-Mart and K-Mart. As part of the transaction, all assets from Dermasilk Brands, Inc. will be

The combination of EPAM’s strong Big Data solutions practice and Sinequa’s unique Cognitive Search and Analytics platform offers customers the ability to gain quick, actionable insights from their

Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a naturally occurring protein that is thought to play a role in autoimmune conditions such

Based in Cambridge of Massachusetts, the new company will develop new comprehensive solutions which will include devices, software, medicine and professional care for diabetes management. The new JV

Strategically located in Seoul, the new site will provide local, regional and global pharmaceutical and biotech companies with a one-stop service for clinical supplies − from cGMP storage,

CHO cells are commonly used in the manufacture of biologics. Merck's new Centinel technology targets genes which play a role in MVM susceptibility. Viral contaminations like MVM can